Skip to main content

Tech transfer

LabsinLove SL, the new ICMAB-CSIC spin off, will push Boron Neutron Cancer Therapy (BNCT) to the next step

Labsinlove SLcentres its research in developing new Boron Neutron Capture Therapy technologies in order to fight cancer. 

Oriol
Oriol
19 March 2024

Labsinlove, S.L. is a recently created company for developing health technologies, which wants to enhance the last step in order to bring new anticancer drugs with a high boron content to actual human treatment. The company is participated by researchers from ICMAB-CSIC and Universidad de Granada. Boron Neutron Capture Therapy (BNCT) BNCT is a binary cancer therapy that combines an external neutron beam and a selective or targeted 10B-containing drug that preferentially concentrates in tumour tissues. The nuclear reaction between the neutron and the boron nucleus generates an alpha particle and a recoiling 7Li nucleus that creates a high degree of localized damage to the tumour cell without damaging healthy tissues.

The company currently has two different business lines. On the one hand, they are dedicated to supply the most used boron compound for this goal 10B enriched boro-phenylalanine (BPA), and on the other hand they are developing new boron compounds, with ICMAB-CSIC participation.

Currently only two drugs are approved for BNCT use in humans: BPA and sodium borocaptate (BSH). However, they are not enough selective towards cancer tissue, which is becoming a bottleneck in BNCT developing. In order to improve that issue, Dr. Rosario Núñez from the Inorganic Materials and Catalysis Laboratory (LMI) research group at ICMAB-CSIC aims to synthesise, test and protect different targeted molecules which include boron clusters, in order to become powerful agents to treat BNCT in humans. Her nearly 30 years of expertise in working with boron cluster-based compounds and materials is a key fact to explore different strategies for linking different kind of  boron cluster derivatives to other molecules and biomolecules in order to have targeted, selectivity-enhancing drugs with high boron content.

Hits: 515